Search
BOCOM International Boosts Sino Biopharmaceutical Target Price to HK$8, Maintains 'Buy' Recommendation
2025-07-21 /
Read about 0 minute
Author：小编
Sino Biopharmaceutical has announced its intention to acquire a 95.09% stake in Innovent Biologics for a maximum sum of US$951 million, with a net transaction value amounting to approximately US$501 million. Upon successful completion of this acquisition, Innovent Biologics will transition into a fully-owned subsidiary of Sino Biopharmaceutical, bringing with it its R&D and management teams, as well as its advanced technology platform. In response, BOCOM International has expressed optimism, revising upwards its adjusted net profit forecasts for Sino Biopharmaceutical by 10-11% for the years 2025-2027. Consequently, the target price has been elevated to HK$8, with the 'Buy' rating retained.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
